| All (n= 28) | Group 1 (n= 14) | Group 2 (n= 14) | ||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Baseline | Month 3 | Month 6 | Baseline | Month 3 | Month 6 | |
Anterior chamber cells (number of patients) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 None | 24 | 26 | 27 | 11 | 13 | 14 | 13 | 13 | 13 |
 0.5+ | 3 | 2 | 1 | 2 | 1 | - | 1 | 1 | 1 |
 1+ | 1 | - | - | 1 | - | - | - | - | - |
 2+ | - | - | - | - | - | - | - | - | - |
 3+ | - | - | - | - | - | - | - | - | - |
 4+ | - | - | - | - | - | - | - | - | - |
Vitreous cells (number of patients) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 None | 14 | 22 | 27 | 8 | 11 | 11 | 6 | 11 | 11 |
 0.5+ | 5 | 5 | 1 | 3 | 3 | 2 | 2 | 2 | 1 |
 1+ | 7 | 1 | - | 3 | - | 1 | 4 | 1 | 2 |
 2+ | 2 | - | - | - | - | - | 2 | - | - |
 3+ | - | - | - | - | - | - | - | - | - |
 4+ | - | - | - | - | - | - | - | - | - |
Vitreous haze (number of patients) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 None | - | 13 | 7 | - | 6 | 3 | - | 7 | 4 |
 0.5+ | 8 | 11 | 16 | 3 | 6 | 9 | 5 | 5 | 7 |
 1+ | 11 | 4 | 5 | 7 | 2 | 2 | 4 | 2 | 3 |
 2+ | 8 | - | - | 3 | - | - | 5 | - | - |
 3+ | 1 | - | - | 1 | - | - | - | - | - |
 4+ | - | - | - | - | - | - | - | - | - |
Corticosteroids dose (median mg/day ± SD) |  |  |  |  |  |  |  |  |  |
 Category 1 (n = 7) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
 Category 2 (n = 13) | 20 ± 15.7 | 12.5 ± 6.8 | 8 ± 5.7 | 25 ± 18.1 | 13.8 ± 8 | 7.8 ± 7.1 | 20 ± 11.4 | 12.5 ± 4.5 | 8.0 ± 1.9 |
 Category 3 (n = 7) | 9 ± 3.1 | 4 ± 2.9 | 3 ± 2.2 | 8.0 ± 2.1 | 4.0 ± 2.5 | 3.0 ± 1.8 | 9.0 ± 4.0 | 5.5 ± 3.5 | 3.0 ± 2.6 |
Visual acuity (mean ±SD) |  |  |  |  |  |  |  |  |  |
 Category 1 | 62 ± 13.3 | 66 ± 13.1 | 61 ± 14.5 | 55 ± 6.2 | 59 ± 12.7 | 51 ± 10.6 | 68 ± 15.4 | 72 ± 11.5 | 69 ± 12.8 |
 Category 2 | 71 ± 16.8 | 72 ± 16.3 | 72 ± 18.1 | 69 ± 15.3 | 70 ± 14.4 | 69 ± 16.9 | 73 ± 20.6 | 77 ± 20.1 | 76 ± 21.3 |
 Category 3 | 72 ± 22.6 | 74 ± 18.3 | 74 ± 15.8 | 66 ± 23.1 | 71 ± 16.3 | 69 ± 14 | 75 ± 24.2 | 77 ± 21 | 76 ± 17.8 |